GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purcha…
$3.56+1.42%
报价 2026-11-13
市值
$1.21B
EV
$1.49B
PE (TTM)
69.4x
预期 PE (FY2026)
11.7x
52 周区间距高点 -6.3%
$1.87$3.80
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 0.32 → 0.35（1.1x） | 10.1 |
| FY+32028-12 | 1.1x | 0.32 → 0.41（1.3x） | 8.6 |
毛利率 88% · TTM 收入 $785M · 基数 EPS 0.32（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| GDRXGoodRx Holdings, Inc. | $1.21B | +1.4% | +0.6% | 89.5% | 69.4x | 8.7x | 8.5x | |
| PLSEPulse Biosciences, Inc. | $3.71B | -3.5% | +1800.0% | 51.6% | – | – | – | 高增长 |
| INVAInnoviva, Inc. | $1.35B | +0.3% | +9.6% | 78.9% | 6.0x | 3.0x | 7.5x | |
| AMPHAmphastar Pharmaceuticals, Inc. | $1.25B | +1.7% | +4.5% | 49.5% | 9.0x | 7.0x | 9.0x | Cheap |
| IRMDIRadimed Corporation | $1.09B | +0.4% | +11.5% | 76.8% | 56.2x | 42.1x | 42.1x | |
| AHCOAdaptHealth Corp. | $1.05B | -2.7% | -10.0% | 15.4% | – | 37.6x | 13.0x | |
| HSTMHealthStream, Inc. | $855.8M | -1.1% | +10.4% | 64.7% | 34.1x | 9.3x | 20.9x | GARP |
| COLLCollegium Pharmaceutical, Inc. | $786.8M | +1.5% | +6.5% | 59.4% | 17.5x | 3.0x | 2.3x | Cheap |
| MDXGMiMedx Group, Inc. | $468.4M | -0.9% | -37.2% | 82.6% | 12.9x | 6.0x | 23.0x | |
| 同行中位数 | – | – | +8.1% | 62% | 15.2x | 7.0x | 13.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $200.4M | $194M | $194.8M | $196M | $203.1M | $203M | $198.6M | $195.3M |
| Gross Margin | 89.5% | 78.4% | 91% | 93.2% | 83.7% | 93.4% | 93.9% | 94% |
| Operating Margin | 11.8% | 10.1% | 11.6% | 7.5% | 13.6% | 11.5% | 9.2% | 10.5% |
| Net Income | $8.5M | $1.2M | $5.4M | $1.1M | $12.8M | $11.1M | $6.7M | $12.3M |
| Diluted EPS | 0.02 | 0 | 0.02 | 0 | 0.04 | 0.03 | 0.02 | 0.03 |
| Operating Cash Flow | $80.8M | $11.8M | $32.9M | $76M | $49.6M | $9.4M | $44.7M | $86.9M |